Delaware Court Recommends Dismissal with Prejudice of Biosimilar Neulasta Suit

Jan 16, 2018

Reading Time : 2 min

In August 2016, Coherus filed an abbreviated Biologics License Application (aBLA), seeking Food and Drug Administration approval to market a biosimilar form of Amgen’s pegfilgrastim product, Neulasta®. Pegfilgrastim is a modified form of granulocyte colony stimulating factor that promotes the creation of white blood cells. After Coherus filed its aBLA, Amgen and Coherus engaged in the exchange of information dictated by the BPCIA, i.e., “the patent dance,” and ultimately agreed–pursuant to 42 U.S.C. § 262(l)(6)(A)–that a single Amgen patent, U.S. Patent No. 8,273,707 (the “’707 patent”), would be included in the lawsuit.

The ’707 patent generally discloses a process for purifying proteins by using column chromatography to separate the proteins of interest from other components. The methods of the ’707 patent include treating the protein mixture with a combination of salts prior to filtering on the column. Critically, both of the independent claims of the ’707 patent require the use of a combination of salts in the loading solution, which must be selected from one of citrate and sulfate, citrate and acetate, or sulfate and acetate.

The salt combination limitations were added by amendment to the claims of the ’707 patent during patent prosecution after Amgen’s claims were rejected as obvious in view of a single reference, Holtz. Holtz was described as teaching a method for purifying a protein by column chromatography; it also discloses salts, such as the citrate, sulfate and acetate salts for use in protein purification. To overcome the obviousness rejection, Amgen argued that Holtz failed to teach combinations of salts to increase the dynamic capacity of a purification column, let alone the “particular combinations of salts recited in the pending claims.” (emphasis in original). Following a second rejection based on Holtz, Amgen reiterated this distinction and submitted a declaration from one of its named inventors to further support its position. Amgen’s claims were subsequently granted.

However, the manufacturing process set forth by Coherus for its biosimilar pegfilgrastim product utilized a different combination of salts not claimed by the ’707 patent. As a result, Amgen was forced to assert infringement under the doctrine of equivalents theory. In its motion to dismiss, Coherus argued that Amgen was foreclosed from arguing equivalence by virtue of prosecution history estoppel. More specifically, Coherus argued that, by narrowing its claims during prosecution to include only the three disclosed salt combinations, Amgen disavowed alternative combinations.

On review, the court found that Amgen clearly and unmistakably surrendered processes using combinations of salts other than those specifically identified in the claims of the ’707 patent. In so doing, the court acknowledged that, had Amgen distinguished its claims from Holtz based solely on the use of a combination of salts, as opposed to the use of a single salt, then no estoppel would apply. But in light of Amgen’s repeated emphasis that its particular combinations of salts provided enhanced benefits over the prior art, including through an inventor declaration that described test results for those particular salt combinations, Amgen was barred from arguing that its claims could reach further.

Amgen Inc., Amgen Manufacturing Limited v. Coherus Biosciences Inc., No. 17-546-LPS-CJB

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.